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Abstract
Taxanes are irreplaceble drugs in treatment of many solid malignancies. In breast cancer they represent the backbone 
of adjuvant therapy and are important option in treatment of advanced and metastatic disease. Since their discovery in 
1960’s they went through a long journey of clinical development and positioning in clinical practise of treatment of early 
breast cancer. Taxanes belong to the fourth group of cytotoxic drugs, which act as mytotic inhibitors, causing the death of 
the cell in metaphase. Clinical trials conducted in patients with breast cancer evaluated diff erent combinations of other che-
motherapeutics with taxanes, diff erent modes of administration, eff ectiveness of diff erent chemotherapy regimens includ-
ing taxanes in diff erent subtypes and stages of the disease and eff ectiveness of individual taxanes in comparison with one 
another. Based on the results of those trials, today the relevant global oncology associations reccomend the use of taxanes in 
treatment of early breast cancer, pointing out their signifi cant benefi t in total reduction of breast cancer mortality and risk 
of disease reccurence by 20-30% comparing to anthracycline only protocols.  The purpose of this literature review was to 
provide comprehensive information about development of taxanes and their position in routine everyday clinical practise. 
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TAKSANI U LIJEČENJU RANOG RAKA DOJKE
Sažetak 
Taksani su nezamjenjivi lijekovi u liječenju mnogih solidnih tumora. U karcinomu dojke predstavljaju okosnicu adju-
vantne terapije i važna su opcija u liječenju uznapredovale i metastatske bolesti. Od njihovog otkrića 1960-ih prošli su dugi 
put kliničkog razvoja i pozicioniranja u kliničkoj praksi liječenja ranog raka dojke. Taksani pripadaju četvrtoj skupini cito-
toksičnih lijekova koji djeluju kao inhibitori mitoze, koji uzrokuju smrt stanice u metafazi. Klinička istraživanja provedena 
na bolesnicama s karcinomom dojke procjenjivala su različite kombinacije drugih kemoterapeutika s taksanima, različite 
načine primjene, djelotvornost različitih kemoterapijskih protokola koji uključuju taksane  u različitim podtipovima i stadi-
jima bolesti te učinkovitosti pojedinih taksana u usporedbi s drugim. Na temelju rezultata tih pokusa, danas relevantne 
globalne onkološke udruge preporučuju uporabu taksana u liječenju ranog raka dojke, pokazujući njihovu značajnu korist 
u ukupnom smanjenju rizika od smrti i povrata bolesti za 20-30% u odnosu na protokole bazirane samo na antraciklinu. . 
Svrha ovog pregleda literature je pružanje sveobuhvatne informacije o razvoju taksana i njihove pozicije u rutinskoj svakod-
nevnoj kliničkoj praksi. 




Various forms of systemic antineoplastic treat-
ment are used in the adjuvant treatment of early 
breast cancer: chemotherapy, endocrine therapy 
and targeted therapy, depending on the stage of 
the disease, biological characteristics of the tumor, 
as well as the characteristics of the patient himself. 
The decision on the optimal form of systemic anti-
neoplastic treatment is made by a multidisciplinary 
team. The backbone of adjuvant chemotherapy in 
the treatment of early and advanced non-metastatic 
breast cancer consists of two groups of cytotoxic 
drugs, anthracyclines and taxanes. Oxford meta-
analysis from 2005 (EBCTCG – Early Breast Cancer 
Trialists’ Collaborative Group),  which included 
194 studies with more than 145 000 patients, 
showed that by using anthracycline-containing ad-
juvant polychemotherapy, the risk of mortality de-
creased by 38% in patients under the age of 50 and 
by 20% in the group from 50 to 69 years of age, 
which clearly confi rmed the position of anthracy-
clines as the gold standard in adjuvant treatment of 
breast cancer in patients under 70 (1).
However, anthracycline effi  cacy in treating 
cancer is limited by a cumulative dose-dependent 
cardiotoxicity (recommended cumulative maxi-
mum of doxorubicin is 450 mg/m2), which can 
cause irreversible heart failure. The cardiotoxicity 
is mediated by cellular mechanisms, responsible 
for increased apoptosis in cardiac myocytes. This 
can cause irreversible structural changes which is 
especially important to keep in mind when treat-
ing population of potentialy curable patients so 
patients should be closely monitored during the 
adjuvant treatment. This problem was one of the 
reasons investigators push forward to fi nd anoth-
er drug alternative in this sett ing (2).
Taxanes have been known since the 1960’s, af-
ter paclitaxel was isolated from pacifi c yew as a 
part of the NCI (National Cancer Institute) experi-
ment, which examined the characteristics of a large 
number of diff erent trees. Given the non-viability 
of raw material consumption, relative to the 
amount of compound obtained, a semi-synthetic 
method of obtaining paclitaxel was developed. 
The clinical course of drug development was slow. 
In 1987 paclitaxel was introduced to treat ovarian 
cancer, breast and lung tumors. In the 1980’s doc-
etaxel was synthesised and it has been used in 
breast cancer therapy since the 1990’s (3).
Taxanes belong to the fourth group of cyto-
toxic drugs, which act as mitotic inhibitors. They 
are inhibitors of mitosis of the spindle fi bers in the 
cell and cause a ‘mitotic block’ at the transition 
from metaphase to anaphase of the cell cycle. They 
are responsible for binding to microtubules, re-
sistance to depolymerization of the resulting poly-
mers, generation of defective microtubules and 
the death of the cell in metaphase. Comparison of 
taxanes showed that docetaxel has a higher affi  ni-
ty for microtubules, achieves bett er transplanta-
tion in the cell, has slower release from the tumor 
cell, induces polymerization stronger and is more 
potent than paclitaxel. It has 12 times stronger cy-
totoxic activity than paclitaxel. In preclinical stud-
ies, docetaxel showed widespread activity in the 
cell cycle (4,5).
The most pronounced side-eff ect of taxanes 
therapy noted in clinical studies and in clinical 
practise is neutropenia which can reach high grade 
in up to 80% of patients treated with docetaxel and 
about 10% of patients developes febrile neutrope-
nia (this eff ect is less common with paclitaxel and 
least common with nab-paclitaxel). Also important 
and dose limiting side-eff ect of therapy is periferal 
neuropathy which occures in high grade in about 
10% of patients. Less frequent side-eff ects include 
anemia, vomiting, stomatitis and edema (6).
Addition of taxanes improves results 
of adjuvant therapy
Taxanes have been used in breast cancer ther-
apy since the 1990s. Their activity was fi rst tested in 
advanced disease studies and then in adjuvant use 
in early and advanced non-metastatic breast can-
cer. The American Food and Drug Administration 
(FDA) approved the use of paclitaxel in the treat-
ment of metastatic breast cancer in 1994. Approval 
was obtained based on a phase III study which 
compared two doses of paclitaxel (175 mg/m2 and 
135 mg/m2 every three weeks) in patients who did 
not respond to prior chemotherapy. It has been 
shown that higher doses of paclitaxel have achieved 
longer median time to progression of the disease 
(TTP), longer median overall survival (OS), and 
longer median survival over 6 months (7).
The development of targeted indications for 
the treatment of non-metastatic breast cancer with 
taxanes has begun with the fi rst generation of ran-
domized clinical trials investigating the addition 
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of taxane to anthracyclines, compared with the use 
of anthracycline only protocols. A large study by 
Henderson and associates, CALGB (Cancer And 
Leukemia Group B) 9344, on over 3, 000 breast 
cancer patients, showed that the addition of pacli-
taxel to anthracycline protocol (to the current 
standard treatment protocol of 4 x AC) provided a 
17% reduction in the relative risk of disease recur-
rence, as well as 18% reduction in the relative risk 
of mortality. Clearly greater benefi t has been 
shown in patients with hormone-independent dis-
ease. However, the CALGB 9344 study did not 
 investigate the same duration of comparable 
chemotherapy protocols, so it positioned taxane 
chemotherapy as an alternative to prolonged an-
thracycline therapy (8). A very similar NSABP 
B-28 study by demonstrated that the addition of 
paclitaxel to anthracycline protocol signifi cantly 
reduced the risk of recurrence, but did not prolong 
OS (90). According to a study PACS 01, by Roche 
et al., docetaxel administration after standard six-
cycle FAC (5-fl uorouracil, doxorubicin, cyclophos-
phamid) protocol, reduced risk of disease recur-
rence by 18%, with a total of 27% reduction in the 
risk of death (10). The study GEICAM (Spanish 
cooperative breast cancer research group)  9906 
showed 23% reduction in risk of disease recur-
rence with the use of weekly paclitaxel after FEC 
(5-fl uorouracil, epirubicin, cyclophosphamid), 
compared to the use of anthracyclines only (11). 
Study by Buzdar et al. confi rmed that improved 
results, obtained in previous adjuvant anthracy-
cline plus taxane studies, were undoubtedly 
caused by addition of taxanes to chemotherapy 
protocol, rather than the longer duration of adju-
vant therapy when adding taxane (12). (Table 1.)
Two studies have relativized the role of taxa-
ne therapy in the adjuvant breast cancer treat-
ment. UK TACT and smaller Albert et al. study 
showed no signifi cant diff erence between DFS 
and OS between group of patients treated with 
anthracycline-based polychemotherapy only and 
patients treated with antracycline plus taxane 
(13,14).
Concomitant use of taxanes and anthracyclines 
and taxanes without antracyclines  
Studies that investigated combination of tax-
anes with doxorubicin, are two major studies, 
BCIRG (Breast Cancer International Research 
Group) 001 and E 2197. In the fi rst study, the com-
parison of anthracycline protocols FAC and TAC 
(docetaxel + doxorubicin + cyclophosphamide) re-
sulted in 28% reduction in risk of disease recur-
rence and 30% reduction in risk of death with TAC 
chemotherapy (15). (Table 1.) The mentioned fi ve-
year follow-up results were maintained after 10 
years of follow-up (16). TAC also showed advan-
tage in DFS compared to FAC in high-risk patients 
without metastases in the lymph nodes (19). Study 
E 2197 demonstrated, on 2 950 patients, after 53 
months follow-up no statistically signifi cant dif-
ference in DFS and OS between AT (doxorubicin + 
docetaxel) and AC (doxorubicin + cyclophospha-
mide) protocol, with both protocols showing un-
expectedly good results, although doubtfully sub-
optimal dose of docetaxel was applied (17). 
USO 9735 demonstrated the advantage of us-
ing taxanes without anthracyclines (comparison 
of TC to AC protocol). After seven years of follow-
up, TC protocol showed the advantage in DFS and 
Table 1. 
FIRST GENERATION OF CLINICAL TRIALS WITH TAXANES
Authors/Trial No. of patients Regimen Results
Henderson et al./CALGB 9344 3,121 pts AC (doxo 60/75/90 mg/m2) 3w +/- paclitaxel 175 mg 3w DFS 70% vs. 65%OS 80% vs. 77%
Mamounas et al./NSABP B-28 3,060 pts AC vs. AC+paclitaxel DFS 72% vs. 76%OS 85% vs. 85%
Roche et al./PACS 01 1,999 pts  FECx6 3w vs. FECx3+docetaxelx3 3w DFS 73% vs. 78%OS 87% vs. 91%
GEICAM 9906 1,246 pts FECx6 3w vs. FECx4 3w+paclitaxelx8 1w DFS 72% vs. 78%OS 87% vs. 90%
BCIRG 001 1,491 pts FACx6 3w vs. TACx6 3w DFS 68% vs. 75%OS 81% vs. 87%
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OS in both older and younger patients, and the 
advantage was more pronounced with longer fol-
low-up, positioning the TC protocol as a standard 
of non-anthracycline protocols (18).
Data from meta-analysis
In order to determine the role of taxanes in 
adjuvant breast cancer treatment, Cochrane 
metaanalysis was performed on 21 000 patients in 
12 studies. The analysis included patients with 
operable disease, stage I - III. Use of taxanes pro-
vided statistically signifi cant prolongation of dis-
ease-free survival (DFS) and overall survival (OS). 
However, subgroup of patients that would have 
the highest benefi t of taxane therapy was not iden-
tifi ed, so it is recommended that all patients with 
stage I disease should be considered for adjuvant 
therapy. In patients with lymph node involve-
ment, adjuvant chemotherapy including taxanes 
showed a DFS prolongation of 24% and OS pro-
longation of 15%, compared to adjuvant non-taxa-
ne treatment. Proportionally achieved risk reduc-
tion was the same in patients with and without 
lymph node involvement. The greatest benefi t of 
chemotherapy has been shown in patients under 
the age of 50, and data were missing for those old-
er than 70 years. This metaanalysis has lead to the 
conclusion that the addition of taxanes to adjuvant 
chemotherapy increases its eff ectiveness, regard-
less of age, nodal status, tumor size and stage, and 
hormone receptor expression. The preferred mode 
of administration is sequential over the concomi-
tant (20).
In 2012, the data from the before mentioned 
EBCTCG metaanalysis from 2005 were updated. 
More than 40 000 patients, treated with the proto-
col including taxanes, were involved in the study. 
The parameters that have infl uenced the reduc-
tion of recurrence and mortality risk were anew 
considered. In the context of taxane aplliance, the 
results showed that the use of taxanes in any com-
bination gave bett er results than disuse and that 
prolonged treatment yielded bett er results com-
pared to earlier interruption of therapy, but with 
the risk of cummulative toxicity, and polychemo-
therapy protocols yielded bett er results compared 
to monochemotherapy. Overall, adjuvant chemo-
therapy based on anthracyclines and taxanes has 
shown a 1/3 reduction in breast cancer mortality 
compared to observation (21).
Weekly paclitaxel - an option of choice
The second generation of adjuvant rand-
omized clinical trials compared diff erent regimens 
using taxanes, the diff erences between sequential 
and concomitant (combination) use and the diff er-
ences between dose dense and standard (three-
week) applications. The CALGB C9741 study 
compared, on 2 000 patients, four paclitaxel regi-
mens; standard sequential application after AC 
regimen and single sequentional A> P> C regimen 
in two-week (dose dense) or three-week intervals. 
After 36 months of monitoring, the two-week pa-
clitaxel regimen showed a signifi cant advantage 
in DFS and OS, but after 69 months, the diff erence 
in OS disappeared. There was no diff erence be-
tween the sequentional drug administration and 
the standard AC-taxane sequence (22). In the BIG 
2-98 study, involving 2900 patients, the diff erence 
between sequential and concurrent administra-
tion of docetaxel with doxorubicin was investigat-
ed. The comparison showed the advantage of the 
sequence A> T> CMF in comparison to A> CMF, 
but the same advantage was not observed in AT> 
CMF when compared to A> CMF. After ten years 
of follow-up, the DFS was not signifi cantly pro-
longed in the case of anthracycline-taxane se-
quence as it was in earlier follow-up, but docetaxel 
showed and maintained signifi cant benefi t in 
high-risk ER (estrogen receptors) dependent pa-
tients (23).
In the study by Shulman et al., comparing 
three protocols, AC> T, TAC and AT, the standard 
sequence AC> T showed signifi cantly bett er DFS 
than TAC and AT, but not signifi cantly bett er OS. 
AT was shown not to be inferior to TAC, thus ad-
ditionally narrowing the indication area for the 
highly toxic TAC protocol (24).
The comparison of taxane based chemothera-
py was performed in a large study by Sparano et 
al., E 1199 which included 4 954 breast cancer pa-
tients. Study compared paclitaxel and docetaxel in 
weekly verusus three-week regimen in sequential 
application after standard four-cycle anthracycline 
(AC) therapy. After 63,8 months of follow-up, the 
benefi t of the weekly paclitaxel and three-week 
docetaxel over three-week paclitaxel, has been 
shown. Weekly paclitaxel showed an advantage in 
DFS and OS (docetaxel only in DFS), in patients 
with positive hormone receptors, as well as in Her2 
negative patients. This made the paclitaxel weekly 
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regimen an option of choice (25). The SWOG 221 
study on 2 700 patients showed, after six years of 
follow-up, that low dose weekly paclitaxel (80mg/
m2 for 12 weeks) was as eff ective as dose-dense pa-
clitaxel (175mg/m2 every two weeks, supported by 
granulocyte colonies growth factors) but signifi -
cantly less toxic (26). A small stage II study of Burk-
ard et al., compared standard docetaxel (4xTC eve-
ry three weeks) with dose dense application (4xTC 
every two weeks), supported by granulocyte colo-
nies growth factors. Both regimens have shown a 
similar profi le of toxicity and tolerability (27). Fur-
ther research results are expected. A study by a 
group of authors from Greece in 2014 showed simi-
lar results in DFS between dose dense administra-
tion of paclitaxel and docetaxel, following the an-
thracycline protocol (4xFEC) in patients with in-
volved lymph nodes, but because of the more 
acceptable toxicity profi le, paclitaxel has been con-
fi rmed as a taxane of choice (28).
Taxanes in HER2 positive disease
In HER2 positive breast cancer, which ac-
counts for about 20% of all breast cancers, patients 
have greater risk of disease relaps and death from 
metastatic disease. In this subgroup of patients 
several studies have positioned taxanes as stand-
ard of treatment in combination with trastuzumab 
immunotherapy (29,30,31). A small, uncontrolled 
single center study (the so-called APT study) by 
Tolaney et al., performed on 406 low-volume tu-
mor patients without aff ected lymph nodes, 
showed 93.3% DFS and 95% OS after 7 years of 
follow-up, with the combination of weekly pacli-
taxel with trastuzumab followed by trastuzumab 
up to one year of therapy. This study has shown 
that, in localized small HER2 positive tumors, it is 
possible to avoid administration of anthracyclines 
in adjuvant treatment (32). Jones and colleagues 
study showed good results with four cycles of 
TCH, followed by trastuzumab up to a total of one 
year of treatment in patients with lower risk dis-
ease (33) and Perez et al. demonstrated the advan-
tage of concomitant application of trastuzumab 
with taxanes versus sequential treatment (34).
DISCUSSION
With the review of historical development of 
targeted indications for use of taxanes, as well as 
the positioning of these drugs in breast cancer 
treatment, several important points of reference 
were made. The major studies, such as the CALGB 
9344, PACS 01 and BCIRG 001 set taxanes to the 
basis of adjuvant breast cancer therapy. Then 
there were studies which raised doubts about the 
advantage of introduction of taxanes with former 
anthracycline treatment standards and urged to 
seek additional confi rmation through new re-
search, such as the studies NCIC CTG MA 21.1 
and the UK TACT. A series of meta-analysis clear-
ly showed the benefi t of introducing taxanes. 
Study E 1199 confi rmed the importance of the 
mode and the regimen of administration itself and 
defi ned weekly paclitaxel and three-week doc-
etaxel as the regimens of choice. There were no 
clear diff erences or advantages of one of the taxa-
nes over the other. A TC protocol was established 
as a standard non- anthracycline protocol for old-
er and cardiovascular patients. Excellent results 
were obtained in the treatment of small Her2 posi-
tive tumors with a combination of taxane and tar-
geted therapy, without previous anthracycline 
chemotherapy. An advantage of the dose-dense 
application regimens has been demonstrated over 
the standard three-week-apart applications. 
From the fi rst confi rmation of the role of taxa-
nes to date, there were no revolutionary innova-
tions or changes in the adjuvant treatment of breast 
cancer, but the progress in optimizing the dose and 
regimen of administration is evident. Signifi cant 
improvement in rate of complete pathological re-
sponses and DFS was reported in neoadjuvant 
treatment with nab-paclitaxel (nanoparticle albu-
min–bound paclitaxel) in comparison with conven-
tional paclitaxel (35). Further investigations with 
this form of drug in adjuvant sett ing are ongoing.  
Today, the most important global oncology 
associations, the American National Comprehensive 
Cancer Network (NCCN) and the European Society for 
Medical Oncology (ESMO) clearly point out the role 
of taxanes added to anthracycline chemotherapy in 
total reduction of mortality risk by 1/3 and in im-
proving adjuvant breast cancer treatment, with less 
pronounced cardiac toxicity. They recommend the 
sequential administration of taxanes after anthra-
cycline regimen and the use of weekly paclitaxel 
and three-weekly docetaxel as the best choice.
Issues that remain open for future discussion 
are numerous indications for off  label use of taxa-
ne therapy, which could serve as a model for new 
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opportunities in the use of these drugs, the issue 
of treatment duration in metastatic disease and 
management of side eff ects, the issue of combina-
tion of taxanes with other cytotoxic drugs and tar-
geted therapies, as well as the issue of new formu-
lations of these drugs.
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